Cited 0 times in
Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 정인경 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 한민경 | - |
dc.date.accessioned | 2021-05-26T16:54:25Z | - |
dc.date.available | 2021-05-26T16:54:25Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182890 | - |
dc.description.abstract | Background: Since September 2015, the initiation of antiviral therapy (AVT) for patients with chronic hepatitis B (CHB)-related cirrhosis has been reimbursed according to the revised Korean Association for the Study of Liver (KASL) guideline, if the patient had hepatitis B virus DNA level ≥ 2,000 IU/L, regardless of aminotransferase or alanine aminotransferase levels. This study investigated whether the KASL guideline implementation reduced the risk of CHB-related hepatocellular carcinoma (HCC) in patients with cirrhosis in South Korea. Methods: A total of 429 patients with CHB-related cirrhosis who initiated AVT between 2014 and 2016 were recruited. The risk of HCC development was compared between patients who initiated AVT before and after September 2015 (pre-guideline [n = 196, 45.7%] vs. post-guideline implementation [n = 233, 54.3%]). Results: Univariate analysis showed that AVT initiation before guideline implementation, older age, male gender, and diabetes significantly predicted increased risk of HCC development (all P < 0.05). Subsequent multivariate analysis showed that AVT initiation before guideline implementation (HR = 1.941), older age (HR = 5.762), male gender (HR = 2.555), and diabetes (HR = 1.568) independently predicted increased risk of HCC development (all P < 0.05). Additionally, multivariate analysis showed that AVT initiation before guideline implementation (HR = 2.309), male gender (HR = 3.058), and lower platelet count (HR = 0.989) independently predicted mortality (P < 0.05). The cumulative incidences of HCC and mortality were significantly higher in patients who initiated AVT before guideline implementation than in those who initiated AVT after guideline implementation (all P < 0.05, log-rank test). Conclusion: The prognosis of patients with CHB-related cirrhosis who initiated AVT improved after guideline implementation according to the revised KASL guideline. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | 대한의학회(The Korean Academy of Medical Sciences) | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | David Sooik Kim | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Kwang Hyub Han | - |
dc.contributor.googleauthor | Yu Rim Lee | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Young Oh Kweon | - |
dc.contributor.googleauthor | Inkyung Jung | - |
dc.contributor.googleauthor | Minkyung Han | - |
dc.contributor.googleauthor | Eun Hwa Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.identifier.doi | 10.3346/jkms.2021.36.e105 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03693 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A05436 | - |
dc.relation.journalcode | J01517 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.identifier.pmid | 33904261 | - |
dc.subject.keyword | Antiviral Therapy | - |
dc.subject.keyword | Guideline | - |
dc.subject.keyword | Hepatitis B | - |
dc.subject.keyword | Hepatocellular Carcinoma | - |
dc.subject.keyword | Management | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 정인경 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.contributor.affiliatedAuthor | 한민경 | - |
dc.citation.volume | 36 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | e105 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.36(16) : e105, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.